Cellectar Biosciences' CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors

Author's Avatar
Nov 05, 2020
Article's Main Image

CLR 131 crosses blood brain barrier delivering drug directly to brain tumors